产品中心Cell Resources
联系我们CONTACT US
400-999-210024小时服务热线
大鼠肺血管平滑肌细胞
Rat Pulmonary Vascular Smooth Muscle Cells
货号：CP-R002
规格：5×10⁵Cells/T25培养瓶
价格： ￥3380
培养基货号： CM-R002
产品概述
大鼠肺血管平滑肌细胞
Cat NO.: CP-R002
-
产品名称：大鼠肺血管平滑肌细胞
-
组织来源：肺组织
-
产品规格：5×10⁵Cells/T25培养瓶
-
细胞简介：
大鼠肺血管平滑肌细胞分离自肺组织；肺是机体的呼吸器官，位于胸腔，左右各一，覆盖于心之上。肺有分叶，左二右三，共五叶。肺经肺系(指气管、支气管等)与喉、鼻相连，故称喉为肺之门户，鼻为肺之外窍。肺血管平滑肌细胞原代分离培养3天后，可见细胞贴壁伸展，细胞形态大小不一，呈梭形、不规则形、三角形或扇形，核卵圆形、居中；2周后细胞汇合，多数细胞伸展呈长梭形，胞浆丰富，有分枝状突起，细胞平行排列成单层或部分区域多层重叠生长，高低起伏；细胞密度低时，常交织成网状；密度高时，则排列为旋涡状或栅栏状。传代后细胞生长较快，4-6天即可汇合，并保持上述形态学特征和生长特点。肺血管平滑肌细胞主要功能：①细胞表面表达介质(ICAM-1和VCAM-1)参与血管壁炎症反应；②是多数重要动脉疾病的靶细胞。肺血管平滑肌细胞与主要病生理变化：①平滑肌增生易致肺动脉高压；②先天性肺动脉狭窄；③肺动脉栓塞。血管平滑肌细胞的加速生长潜能是血管疾病进展的关键因素，最新研究表明血管平滑肌细胞表达的ICAM-1和VCAM-1能促进血管壁的炎症反应，并且与血管疾病的发展及稳定性有关。
-
方法简介：
普诺赛实验室分离的大鼠肺血管平滑肌细胞采用胰蛋白酶 - 胶原酶联合消化法结合差速贴壁法制备而来，细胞总量约为5×10⁵cells/瓶。
-
质量检测：
普诺赛实验室分离的大鼠肺血管平滑肌细胞经α-SMA免疫荧光鉴定，纯度可达90%以上，且不含有HIV-1、HBV、HCV、支原体、细菌、酵母和真菌等。
-
培养信息：
包被条件 培养基 含FBS、生长添加剂、Penicillin、Streptomycin等 产品货号 CM-R002 换液频率 每2-3天换液一次 生长特性 贴壁 细胞形态 成纤维细胞样 传代特性 可传5代左右；3代以内状态最佳 消化液 0.25%胰蛋白酶 大鼠肺血管平滑肌细胞体外培养周期有限；建议使用普诺赛配套的专用生长培养基及正确的操作方法来培养，以此保证该细胞的最佳培养状态。
参考文献
-
Mesenchymal stromal cell-derived exosomes improve pulmonary hypertension through inhibition of pulmonary vascular remodeling (2003-00-20)
作者：Shanshan Zhang:1.The Second Hospital of Shandong University, No. 247, Beiyuan Dajie, Jinan, 250033, People's Republic of China. ; Xiaoli Liu:1.Department of Hematology, The Second Hospital of Shandong University, Jinan, People's Republic of China. ; 2.Institute of Biotherapy for Hematological Malignancies, The Second Hospital of Shandong University, Jinan, People's Republic of China. ; Li Li Ge:1.Department of Special Inspection, The Second Hospital of Shandong University, Jinan, People's Republic of China. ; Kailin Li:1.Institute of Medical Science, Central Research Laboratory, The Second Hospital of Shandong University, No. 247, Beiyuan Dajie, Jinan, 250033, People's Republic of China. ; Yongchao Sun:1.Department of Medicine, Jinan Vocational College of Nursing, Jinan, People's Republic of China. ; Fang Wang:1.Institute of Medical Science, Animal center, The Second Hospital of Shandong University, Jinan, People's Republic of China. ; Ying Han:1.Institute of Medical Science, Ani
期刊：Mesenchymal stromal cell-derived exosomes improve pulmonary hypertension through inhibition of pulmonary vascular remodeling
影响因子 ：5.8
引用产品： 大鼠肺血管平滑肌细胞
-
The protective effects of MSC‐EXO against pulmonary hypertension through regulating Wnt5a/BMP signalling pathway (2010-00-20)
作者：Zhaohua Zhang:1.Department of Pediatrics, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China. ; LiLi Ge:1.The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China. ; 2.Department of Cardiac Ultrasound, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China. ; Shanshan Zhang:1.Department of Emergency, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China. ; Jue Wang:1.Central Research Laboratory, Institute of Medical Science, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China. ; Wen Jiang:1.Central Research Laboratory, Institute of Medical Science, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China. ; Qian Xin:1.Central Research Laboratory, Institute of Medical Science, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China. ; Yun Luan:1.Central Research Laboratory, Inst
期刊：The protective effects of MSC‐EXO against pulmonary hypertension through regulating Wnt5a/BMP signalling pathway
影响因子 ：5.3
引用产品： 大鼠肺血管平滑肌细胞
-
Dacomitinib, a new pan-EGFR inhibitor, is effective in attenuating pulmonary vascular remodeling and pulmonary hypertension (2005-09-20)
作者：Xiufeng Yu:1.College of Medical Laboratory Science and Technology, Harbin Medical University (Daqing), Daqing 163319, PR China; Central Laboratory of Harbin Medical University (Daqing), Daqing 163319, PR China; Department of Biopharmaceutical Sciences, College of Pharmacy, Harbin Medical University, Harbin 150081, PR China; Department of Hepatic Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin 150081, PR China. ; Xijuan Zhao:1.College of Medical Laboratory Science and Technology, Harbin Medical University (Daqing), Daqing 163319, PR China; Central Laboratory of Harbin Medical University (Daqing), Daqing 163319, PR China; Department of Biopharmaceutical Sciences, College of Pharmacy, Harbin Medical University, Harbin 150081, PR China. ; Junting Zhang:1.Central Laboratory of Harbin Medical University (Daqing), Daqing 163319, PR China; Department of Biopharmaceutical Sciences, College of Pharmacy, Harbin Medical University, Harbin 150081, PR China. ; YiYing L
期刊：Dacomitinib, a new pan-EGFR inhibitor, is effective in attenuating pulmonary vascular remodeling and pulmonary hypertension
DOI：10.1016/j.ejphar.2019.02.008
影响因子 ：5.0
引用产品： 大鼠肺大动脉平滑肌细胞 , 大鼠肺血管平滑肌细胞
FAQs
Q：{{item.question}}
A：
产品资料
识别码示意图
